Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Krystal Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Krystal Biotech's regulatory disclosures and financial reporting.
Krystal Biotech (KRYS) President of R&D, Director and 10% owner Suma M. Krishnan filed a Form 4 disclosing modest open-market sales executed on 9–10 July 2025 under a Rule 10b5-1 trading plan adopted 12 Sep 2024.
- Shares sold (reporting person): 7,000 common shares at weighted-average prices of $150.14–$151.39.
- Shares sold (spouse): 7,127 shares at $150.07–$151.39 under a separate 10b5-1 plan.
- Total shares disposed: 14,127, representing roughly 0.5% of their combined holdings.
- Remaining ownership: 1,456,711 shares directly; 90,000 via SMK Trust; 50,000 via Krishnan Family Trust; spouse retains 1,525,929 shares.
The transactions slightly reduce insider exposure yet leave the couple with an aggregate stake of about 3.1 million shares, signalling continuing alignment with shareholders. Because the sales were pre-scheduled, they carry limited information about the company’s near-term outlook.
On 30 June 2025, Krystal Biotech (KRYS) filed a Form 4 reporting that independent director Julian S. Gangolli received 5,000 stock options with an exercise price of $137.46 and a 10-year term expiring 30 June 2035. The award vests in 12 equal monthly tranches through June 2026, aligning the director’s incentives with shareholder value over the next year. No common shares were bought or sold, and the grant represents potential dilution of well under 0.1 % of outstanding shares, making it immaterial from a capitalization standpoint.
Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an equity compensation grant to director Daniel Janney on 30 June 2025.
- Type of security: Non-qualified stock option (right to buy common shares).
- Quantity: 5,000 options.
- Exercise price: $137.46 per share.
- Vesting schedule: Awards vest in equal monthly installments over 12 months beginning on the grant date.
- Expiration: 30 June 2035 (10-year term).
- Post-transaction beneficial ownership: 5,000 derivative securities reported as directly held; no change in non-derivative share ownership was reported.
The filing represents a routine director compensation grant. The size—5,000 options—equates to a low single-digit percentage of average daily trading volume and an immaterial fraction of KRYS’s ~25 million shares outstanding, implying limited dilution or market impact. No open-market purchases or sales were reported.